US Biosimilars Strength Rides On The Wings Of Oncology Launches

 
• By Jessica Merrill

Herceptin, Avastin and Rituxan biosimilars have achieved notable market penetration, outpacing other biosimilar launches and contributing to lower drug spending, according to a report from Amgen.

piggy banks
Biosimilars are saving the US healthcare system money, an Amgen report says • Source: Alamy

More from Drug Pricing

More from Scrip